Related Experiment Video
Updated: Aug 7, 2025

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
Published on: October 16, 2021
High lipoprotein(a) levels and mitral valve disease: A systematic review
Walter Masson1, Leandro Barbagelata1, Pablo Oberti1
1Servicio de Cardiología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Insights
Lipoprotein(a) [Lp(a)] may be linked to mitral valve calcification, but its role in mitral valve dysfunction is unclear. Further research is needed to confirm these associations in heart disease.
Area of Science:
- Cardiology
- Genetics
- Epidemiology
Background:
- Lipoprotein(a) [Lp(a)] is a recognized risk factor for atherosclerotic cardiovascular diseases.
- Previous research on Lp(a) and mitral valve disease is limited and yields conflicting results.
- Understanding the Lp(a) and mitral valve disease link is crucial for cardiovascular risk assessment.
Conclusions:
- The association between Lp(a) and mitral valve calcification appears robust, aligning with findings in aortic valve disease.
- The role of Lp(a) in mitral valve dysfunction requires further investigation.
- Additional research is necessary to elucidate the complex relationship between Lp(a) and mitral valve disease.
Aims:
The role of lipoprotein(a) [Lp(a)] as a possibly causal risk factor for atherosclerotic artery disease and aortic valve stenosis has been well established. However, the information available on the association between Lp(a) levels and mitral valve disease is limited and controversial. The main objective of the present study was to assess the association between Lp(a) levels and mitral valve disease.
Data Synthesis:
This systematic review was performed according to PRISMA guidelines (PROSPERO CRD42022379044). A literature search was performed to detect studies that evaluated the association between Lp(a) levels or single-nucleotide polymorphisms (SNPs) related to high levels of Lp(a) and mitral valve disease, including mitral valve calcification and valve dysfunction. Eight studies including 1,011,520 individuals were considered eligible for this research. The studies that evaluated the association between Lp(a) levels and prevalent mitral valve calcification found predominantly positive results. Similar findings were reported in two studies that evaluated the SNPs related to high levels of Lp(a). Only two studies evaluated the association of Lp(a) and mitral valve dysfunction, showing contradictory results.
Conclusions:
This research showed disparate results regarding the association between Lp(a) levels and mitral valve disease. The association between Lp(a) levels and mitral valve calcification seems more robust and is in line with the findings already demonstrated in aortic valve disease. New studies should be developed to clarify this topic.
Related Concept Videos
Mitral Valve Prolapse I: Introduction
Mitral Stenosis II: Clinical features and Diagnostic Tests
Mitral Valve Prolapse II: Assessment and Management
Mitral Stenosis I: Introduction
Mitral Stenosis III: Medical Management
Mitral Regurgitation II: Clinical Features and Diagnostic Tests

